NAD+ Injections vs Oral NAD+ Precursors for Aging Dogs: My Verdict

Should an old dog get a NAD+ shot or a daily precursor to support normal cellular energy?

My call is oral precursors first. Injections sound stronger because they bypass digestion, yet for NAD+ biology that advantage rarely translates into steadier support for normal aging function. Oral nicotinamide riboside, nicotinamide mononucleotide, niacin, and nicotinamide feed the normal salvage pathways dogs already use to maintain NAD+, while intact NAD+ itself has poor oral stability and injected NAD+ has very thin canine data, added handling stress, and a short presence in blood.

A senior spayed Labrador retriever shuffles into my exam room with her owner, tail still wagging but slow to rise from the lobby rug. The owner has printed a price sheet for a mobile NAD+ injection service and a screenshot of an oral precursor chew, asking which will restore puppy spark. Her morning walk has slipped from 25 minutes to 10 minutes before she sits and pants, and evening stairs now need coaxing with treats. The decision feels urgent because winter ice is coming. I hear this fork weekly: dramatic shot now versus quiet daily support.

Why can’t you just give NAD+ itself by mouth?

NAD+ itself does not survive digestion intact.

The molecule is large, charged, and built to work inside cells, not to cross from gut lumen to bloodstream whole. Mammals maintain NAD+ pools by recycling nicotinamide and by building from dietary niacin, nicotinamide, tryptophan, nicotinamide riboside, and nicotinamide mononucleotide through well-mapped salvage routes, as reviewed by Nature Reviews Molecular Cell Biology. That biology explains the formulation split you see on shelves: credible orals do not contain much intact NAD+; they contain precursors intended to support normal NAD+ biosynthesis.

Check the label with that filter. Look for a named precursor, milligrams per chew or capsule, feeding directions by weight, lot number, and a quality program. Skim past proprietary cellular blends with no amounts. Request a certificate of analysis when it is not posted.

Do injections actually raise tissue NAD+ better than a daily chew?

On paper, intravenous or subcutaneous delivery avoids first-pass digestion. In practice for dogs, the differential is wider: endocrinopathy such as hypothyroidism, anemia, chronic kidney disease, orthopedic pain, cognitive change, and deconditioning can all mimic low energy, and none are fixed by a NAD+ spike. Work that differential in prose and in the exam room before recommending anything.

Injections also carry tradeoffs owners underestimate. They require veterinary handling, restraint, aseptic technique, and monitoring for infusion reactions, nausea, or vascular irritation reported in human NAD+ infusion literature. Tissue uptake is transient, repeat visits add stress for arthritic seniors, and no established canine dose, interval, or target blood level exists for longevity support. A brief post-visit perk often reflects fluids, attention, and placebo-by-proxy rather than durable change in normal mitochondrial function.

A lanky cattle-dog mix from a farm property shows where that tradeoff bites. His owner drove him in for two veterinary NAD+ injections after a neighbor praised them, hoping for steadier farm rounds. He panted through restraint, paced that evening, then trotted brightly the next morning before fading again by day three. His regular half-mile pasture loop to the barn shrank to a 0.6-mile out-and-back with two long sits, unchanged from baseline within a week. We had skipped dental pain, low thyroid screening, and a lameness exam in the rush for a shot, and the oral precursor we discussed sat unopened while we chased the spike.

What do oral precursors do for normal cellular function?

Precursors support normal NAD+ recycling for redox reactions, sirtuin signaling, and DNA-maintenance enzymes involved in everyday cellular housekeeping. Among them, nicotinamide riboside has the clearest oral bioavailability signal in mammals, with dose-dependent increases in blood NAD+ metabolites after oral dosing shown by Nature Communications. That does not prove added years or disease treatment in dogs. It supports a structure/function role: nutritional support for normal energy metabolism and healthy aging, not a cure.

Within orals, I rank evidence in this order. Nicotinamide riboside leads on pharmacokinetic data. Nicotinamide mononucleotide follows, with growing but less consistent oral data and more product-quality variability. Niacin and nicotinamide have long nutritional history for meeting B3 needs, summarized by the NIH Office of Dietary Supplements, yet high niacin doses risk flushing and hepatic stress, so I do not push food B3 into pharmacologic ranges.

Demand the same rigor you would for joint support. Compare precursors head-to-head on precursor identity, mg per dose, third-party testing, and palatability for daily use. For context on sorting stiffness from true joint disease before you credit any supplement, see Arthritis vs. Normal Aging Stiffness in Dogs: How to Tell the Difference. For how injection-versus-oral tradeoffs play out in joints, the reasoning parallels Chondroprotectant Injections vs. Oral Joint Supplements for Dogs: My Call and Hyaluronic Acid Injections vs. Oral Chews for Dogs: Which One Actually Fits Your Dog’s Joint.

Which dogs should you screen before you try either route?

Lead with the exam, then the bowl. Obtain body condition, muscle condition, gait assessment, oral exam, and baseline senior labs when age or signs warrant it. Consider thyroid panel, urinalysis, blood pressure, and orthopedic and neurologic exams where the pattern points that way. Review diet for complete B-vitamin nutrition and review drugs that affect appetite, gut tolerance, or liver values. This sequence prevents crediting NAD+ support for improvement that actually came from pain control, dental care, or thyroid replacement, and it prevents missing immune-mediated or neoplastic differentials while trialing a chew.

What sequence do I use in practice?

Follow a tight order. Confirm senior status and rule out medical mimics. Stabilize diet, weight, sleep, dental pain, and exercise first. Choose one oral precursor with transparent mg, feed it consistently for 8 to 12 weeks, and track two markers such as walk duration and stair willingness. Reassess. Reserve injectable NAD+ only for direct veterinary supervision when oral use is impossible or when a clinician judges a supervised trial warranted, with informed consent about limited canine data.

A stocky senior beagle living in a third-floor walk-up shows when I bend that usual advice. He vomited every flavored chew and powder we tried, including two precursor brands and a bland-food hide, and his owner could not pill him without a bite risk. His hind-end weakness still needed a full workup for intervertebral disease and endocrinopathy, yet daily oral dosing was functionally impossible. Under his primary veterinarian’s supervision we discussed a short, monitored in-clinic plan while we addressed pain and conditioning, with weight as our guardrail after he dropped from 36 pounds to 31 pounds during the appetite slump. The exception proves the rule: change the route only when anatomy, behavior, or supervised care blocks the preferred path.

Where does this land? For most aging dogs, a tested oral precursor fed daily supports normal NAD+ metabolism with less stress, lower cost per day of compliance, and clearer tracking than injections. Injections remain a clinic procedure with thin longevity evidence in dogs. Pick the boring consistent route, measure function, and let the differentials guide you.